Discover the most talked about and latest scientific content & concepts.

J Hall, A Brault, F Vincent, S Weng, H Wang, D Dumlao, A Aulabaugh, D Aivazian, D Castro, M Chen, J Culp, K Dower, J Gardner, S Hawrylik, D Golenbock, D Hepworth, M Horn, L Jones, P Jones, E Latz, J Li, LL Lin, W Lin, D Lin, F Lovering, N Niljanskul, R Nistler, B Pierce, O Plotnikova, D Schmitt, S Shanker, J Smith, W Snyder, T Subashi, J Trujillo, E Tyminski, G Wang, J Wong, B Lefker, L Dakin and K Leach
Cyclic GMP-AMP synthase (cGAS) initiates the innate immune system in response to cytosolic dsDNA. After binding and activation from dsDNA, cGAS uses ATP and GTP to synthesize 2', 3' -cGAMP (cGAMP), a cyclic dinucleotide second messenger with mixed 2'-5' and 3'-5' phosphodiester bonds. Inappropriate stimulation of cGAS has been implicated in autoimmune disease such as systemic lupus erythematosus, thus inhibition of cGAS may be of therapeutic benefit in some diseases; however, the size and polarity of the cGAS active site makes it a challenging target for the development of conventional substrate-competitive inhibitors. We report here the development of a high affinity (KD = 200 nM) inhibitor from a low affinity fragment hit with supporting biochemical and structural data showing these molecules bind to the cGAS active site. We also report a new high throughput cGAS fluorescence polarization (FP)-based assay to enable the rapid identification and optimization of cGAS inhibitors. This FP assay uses Cy5-labelled cGAMP in combination with a novel high affinity monoclonal antibody that specifically recognizes cGAMP with no cross reactivity to cAMP, cGMP, ATP, or GTP. Given its role in the innate immune response, cGAS is a promising therapeutic target for autoinflammatory disease. Our results demonstrate its druggability, provide a high affinity tool compound, and establish a high throughput assay for the identification of next generation cGAS inhibitors.
Facebook likes*
News coverage*
SC clicks
Immunity, Rheumatology, Rheumatoid arthritis, Immunosuppressive drug, Systemic lupus erythematosus, Innate immune system, Lupus erythematosus, Immune system
MeSH headings
comments powered by Disqus

* Data courtesy of